Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer ; volume:20 ; number:1 ; day:4 ; month:9 ; year:2018 ; pages:1-13 ; date:12.2018
Breast cancer research ; 20, Heft 1 (4.9.2018), 1-13, 12.2018
- Creator
-
Buus, Richard
- Contributor
-
Yeo, Belinda
Brentnall, Adam R.
Klintman, Marie
Cheang, Maggie Chon U.
Khabra, Komel
Sestak, Ivana
Gao, Qiong
Cuzick, Jack
Dowsett, Mitch
SpringerLink (Online service)
- DOI
-
10.1186/s13058-018-1040-9
- URN
-
urn:nbn:de:101:1-2018102222304125377229
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Buus, Richard
- Yeo, Belinda
- Brentnall, Adam R.
- Klintman, Marie
- Cheang, Maggie Chon U.
- Khabra, Komel
- Sestak, Ivana
- Gao, Qiong
- Cuzick, Jack
- Dowsett, Mitch
- SpringerLink (Online service)
Other Objects (12)
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer